Javelin and Myriad terminate merger pact

Javelin Pharmaceuticals and Myriad Pharmaceuticals have officially terminated their merger pact, clearing the way for Javelin to accept Hospira's $141 million buyout offer. Hospira's offer was considerably higher than Myriad's $90 million purchase price, and it included $4.4 million to cover the termination fee. Javelin submitted an NDA for its postoperative pain therapy Dyloject last December. Report